AMC – Credit Suisse rates the stock as Neutral
The broker makes no changes to its forecasts, Neutral rating or $17.20 target price.
Read MoreBroker News
STP – Morgans rates the stock as Add
Morgans initiates coverage on Step One Clothing with an Add rating and price target of $3.20.
Read MoreIPL – Credit Suisse rates the stock as Neutral
The Neutral rating is retained and the target price increases to $3.14 from $3.01.
Read MoreNCM – Morgans rates the stock as Add
The Add rating and $30.43 target price are maintained.
Read MoreLNK – Morgans rates the stock as Add
The target price remains at the Carlyle bid price and the Add rating is maintained.
Read MoreANP – Morgans rates the stock as Speculative Buy
Morgans raises its target price to $0.58 from $0.45. The Speculative Buy rating is retained.
Read MoreHT1 – Credit Suisse rates the stock as Outperform
Target price is steady at $2.50. Outperform rating retained.
Read MoreXRO – Macquarie rates the stock as Underperform
The $130 target price and Underperform rating are maintained.
Read MoreHCW – Morgans rates the stock as Add
Morgans initiates coverage on HealthCo Healthcare & Wellness REIT with an Add rating and $2.48 target.
Read MoreECX – Macquarie rates the stock as Outperform
The Outperform rating and $2.82 target price are retained for Eclipx Group.
Read MoreCIP – Credit Suisse rates the stock as Neutral
The Neutral rating and target price of $3.83 are retained.
Read MoreANN – Macquarie rates the stock as Underperform
Macquarie sees price as a more relative factor in the 2H and on current dynamics, retains Sell. Target falls to $30.70 from $32.00.
Read MoreNCM – Credit Suisse rates the stock as Outperform
Outperform rating and $31 target maintained.
Read MoreRED – Morgans rates the stock as Add
Morgans leaves its $0.33 target price and Add rating unchanged following Red 5’s update on construction at the King of the Hills gold project (on-track).
Read MoreAUB – Macquarie rates the stock as Outperform
Macquarie says management’s new five-year EPS targets sharply exceed the broker’s. Outperform and $25.52 target retained.
Read MoreAUB – Credit Suisse rates the stock as Outperform
Outperform rating maintained. Target is $25.70.
Read MoreDBI – Morgans rates the stock as Add
To reflect Dalrymple Bay infrastructure’s recent bond issue and Morgans updated interest and inflation rate assumptions, the broker’s target falls to $2.36 from $2.49. The Add rating is unchanged.
Read MoreJHX – UBS rates the stock as Buy
Target rises to $59.80 from $54.70, Buy retained.
Read MoreNHF – Credit Suisse rates the stock as Neutral
Neutral and $6.70 target retained.
Read MoreALQ – Morgans rates the stock as Hold
Morgans raises the target to $13.17 from $12.45 and retains a Hold rating.
Read MorePWR – Morgans rates the stock as Add
Add rating retained. Target rises to $4.16 from $4.02.
Read MorePME – Citi rates the stock as Sell
Citi initiates coverage on Pro Medicus with a Sell rating and a $45 target price.
Read MoreORI – Credit Suisse rates the stock as Neutral
Credit Suisse is constructive regarding Orica yet downgrades to Neutral from Outperform ahead of the FY21 result. The broker upgrades the target to $17.23 from $16.11.
Read MoreLNK – Citi rates the stock as Neutral
Citi lifts its target to $5.00 from $4.75 and retains a Neutral rating.
Read MoreNWL – Credit Suisse rates the stock as Outperform
Outperform rating and $17.80 target maintained.
Read MorePDL – Morgans rates the stock as Add
Morgans maintains an Add rating, believing the valuation is undemanding and the balance sheet remains strong. Target is reduced to $7.80 from $8.05.
Read MoreING – Citi rates the stock as Buy
Target remains $4.55 with an unchanged Buy rating.
Read MoreDHG – Morgans rates the stock as Hold
The broker lifts its target price to $5.36 from $5.22 and maintains its Hold rating on valuation.
Read MoreCSR – Credit Suisse rates the stock as Neutral
Neutral retained, target rises to $6.70 from $6.00.
Read MoreDMP – Citi rates the stock as Neutral
Citi maintains a Neutral rating and reduces the target to $144.25 from $148.70.
Read MoreGNC – Credit Suisse rates the stock as Neutral
Target is increased to $6.35 from $6.16. A Neutral rating is maintained on valuation although the broker acknowledges the upside risk.
Read MoreAMC – UBS rates the stock as Buy
UBS lowers its target to $18.83 from $18.93. Buy-rated.
Read MoreCTP – Morgans rates the stock as Hold
The broker lowers its target price to $0.12 from $0.13 and maintains its Hold rating.
Read MoreNHF – Macquarie rates the stock as Neutral
Neutral rating retained. Target rises to $7.15 from $7.05.
Read MoreIAG – Morgans rates the stock as Add
Morgans downgrades its FY22 EPS forecast by -26% and reduces its target price to $5.36 from $5.64. The analyst retains an Add rating.
Read MoreCHC – Credit Suisse rates the stock as Neutral
The broker revises FY22 and FY23 estimates up by 11.6% and 10.6%, increasing the target to $19.37 from $18.87. Neutral maintained.
Read MoreWBC – Citi rates the stock as Buy
The Buy rating and target price of $30.00 are retained.
Read MorePSI – Macquarie rates the stock as Neutral
The broker also believes future acquisitions are already priced in and retains a Neutral rating. Target is raised to $4.95 from $4.00.
Read MoreAUB – Macquarie rates the stock as Outperform
The broker retains Outperform and a $25.52 target.
Read MoreORG – UBS rates the stock as Buy
Buy rating retained. Target is raised to $6.00 from $5.85.
Read More
